First Time Loading...

Tibet Rhodiola Pharmaceutical Holding Co
SSE:600211

Watchlist Manager
Tibet Rhodiola Pharmaceutical Holding Co Logo
Tibet Rhodiola Pharmaceutical Holding Co
SSE:600211
Watchlist
Price: 46.85 CNY -1.06%
Updated: Apr 29, 2024
Section:
 

Relative Value

The Relative Value of one Tibet Rhodiola Pharmaceutical Holding Co stock under the Base Case scenario is 81.73 CNY. Compared to the current market price of 46.85 CNY, Tibet Rhodiola Pharmaceutical Holding Co is Undervalued by 43%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
81.73 CNY
Undervaluation 43%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

3.7
P/S
P/S
Price to Sales
3.7
vs History
85
vs Industry
33
Median 3Y
4.3
Median 5Y
4.8
Industry
2.4
Forward
2.7
More Details
14.5
P/E
P/E
Price to Earnings
14.5
vs History
93
vs Industry
35
Median 3Y
28.3
Median 5Y
27.5
Industry
23.2
Forward
10.4
More Details
10.9
P/OCF
P/OCF
Price to OCF
10.9
vs History
87
vs Industry
33
Median 3Y
17.5
Median 5Y
17.5
Industry
15.5
More Details
11
P/FCFE
P/FCFE
Price to FCFE
11
vs History
90
vs Industry
33
Median 3Y
14.8
Median 5Y
16
Industry
23.5
More Details
3.5
P/B
P/B
Price to Book Value
3.5
vs History
57
vs Industry
25
Median 3Y
3.7
Median 5Y
3.6
Industry
2.2
More Details
3.4
EV/S
EV/S
Enterprise Value to Sales
3.4
vs History
82
vs Industry
32
Median 3Y
3.8
Median 5Y
4.3
Industry
2.5
Forward
2.6
More Details
3.6
EV/GP
EV/GP
Enterprise Value to Gross Profit
3.6
vs History
85
vs Industry
53
Median 3Y
4.2
Median 5Y
4.9
Industry
5.2
More Details
8.8
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
8.8
vs History
93
vs Industry
36
Median 3Y
20.3
Median 5Y
20.3
Industry
12.5
Forward
7.7
More Details
8.8
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
8.8
vs History
93
vs Industry
40
Median 3Y
20.3
Median 5Y
20.3
Industry
17.2
More Details
10.1
EV/OCF
EV/OCF
Enterprise Value to OCF
10.1
vs History
84
vs Industry
37
Median 3Y
15.2
Median 5Y
15.1
Industry
15.1
More Details
10.4
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
10.4
vs History
77
vs Industry
34
Median 3Y
13.3
Median 5Y
14.1
Industry
19.7
More Details
3.2
EV/IC
EV/IC
Enterprise Value to IC
3.2
vs History
68
vs Industry
25
Median 3Y
4
Median 5Y
3.9
Industry
2
More Details

Multiples Across Competitors

Competitors Multiples
Tibet Rhodiola Pharmaceutical Holding Co Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Tibet Rhodiola Pharmaceutical Holding Co
SSE:600211
11.5B CNY 3.7 14.5 8.8 8.8
US
Mckesson Corp
NYSE:MCK
71.2B USD 0.2 23.7 16.5 19.1
US
Cencora Inc
NYSE:COR
48B USD 0.2 25.7 13.2 18.5
US
Amerisourcebergen Corp
NYSE:ABC
35.4B USD 0.1 20.9 11.3 15.2
US
Cardinal Health Inc
NYSE:CAH
25.2B USD 0.1 39.4 8.8 11.9
US
Henry Schein Inc
NASDAQ:HSIC
9.5B USD 0.8 22.7 11.9 16
KR
Celltrion Healthcare Co Ltd
KOSDAQ:091990
12.2T KRW 5.9 89.6 59.9 61.9
CN
Sinopharm Group Co Ltd
HKEX:1099
67.3B HKD 0.1 7 1.7 2
CN
Huadong Medicine Co Ltd
SZSE:000963
57.5B CNY 1.4 21.4 15.5 15.5
IT
Amplifon SpA
MIL:AMP
7.1B EUR 3.1 45.9 14.8 29.2
CN
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
50.8B CNY 0.2 13.5 8 8

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 132,400+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.